MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.92
-0.22 (-0.63%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close35.14
Open34.94
Bid0.00 x 800
Ask0.00 x 800
Day's Range34.72 - 35.45
52 Week Range30.33 - 47.82
Volume3,800,634
Avg. Volume4,777,254
Market Cap18.006B
Beta (3Y Monthly)1.30
PE Ratio (TTM)33.32
EPS (TTM)1.05
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est44.63
Trade prices are not sourced from all markets
  • David Einhorn's Top 4 Sells in 3rd Quarter
    GuruFocus.com2 days ago

    David Einhorn's Top 4 Sells in 3rd Quarter

    Top sells include Mylan and GM. Investor also axed Apple and Micron

  • Momenta Moves On
    Motley Fool3 days ago

    Momenta Moves On

    The biotech is shifting focus away from biosimilars and toward its pipeline of immune drugs.

  • How Bausch Health’s Financials Look in November
    Market Realist3 days ago

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017, a ~4% YoY decline. Bausch Health generated revenues of $6.26 billion over the first nine months of this year compared to $6.56 billion in the same period the prior year, reflecting a ~5% YoY decline.

  • How Wall Street Analysts View Bausch Health in November
    Market Realist3 days ago

    How Wall Street Analysts View Bausch Health in November

    On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.

  • TheStreet.com5 days ago

    Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

    during the fast paced "Lightning Round" on Tuesday night's "Mad Money" program, TheStreet's Jim Cramer said, "In that genre, we like Mylan N.V. A recommendation from Jim Cramer of MYL is a good place to start but let's do a quick check of the charts and indicators to see if this is a good time to approach the long side of MYL. In this daily bar chart of MYL, below, we can see a downtrend from January to October but this could be a different story on the weekly chart.

  • Benzinga5 days ago

    Jim Cramer Weighs In On Dropbox, Teva And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would stay away from Sociedad Quimica y Minera de Chile (NYSE: SQM ). He doesn't see any edge that could make him money in the stock. ...

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of MYL earnings conference call or presentation 5-Nov-18 10:00pm GMT

    Q3 2018 Mylan NV Earnings Call

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Reuters9 days ago

    Mylan and Theravance's COPD treatment gets FDA approval

    Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems. The treatment, Yupelri https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf, is a once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough. Yupelri belongs to a class of drugs called long-acting muscarinic antagonists (LAMA), with the existing treatment options primarily being hand-held devices such as Boehringer Ingelheim's Spiriva.

  • Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3
    Zacks10 days ago

    Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3

    Momenta (MNTA) posts narrower-than-expected loss in the third quarter, while revenues fall short of estimates.

  • PR Newswire10 days ago

    Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease

    DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the  New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year.

  • Hedge Funds Think This Drugmaker is on the Verge of a Breakout
    Insider Monkey11 days ago

    Hedge Funds Think This Drugmaker is on the Verge of a Breakout

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]

  • Mylan’s Major Drivers: Biosimilars and Asset Acquisitions
    Market Realist11 days ago

    Mylan’s Major Drivers: Biosimilars and Asset Acquisitions

    On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.

  • Europe: Key Growth Driver for Mylan
    Market Realist11 days ago

    Europe: Key Growth Driver for Mylan

    In the third quarter, Mylan (MYL) reported net sales of $1.04 billion from the European market, which is a flat performance on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the company has witnessed strong demand for branded generics and over-the-counter products in the European market. According to Mylan’s investor presentation, the company has a presence in 35 countries and offers more than 1,500 products in the European market. Mylan is already a leader in terms of value and volume in France and Italy’s generic drug markets.

  • InvestorPlace11 days ago

    Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow

    Whenever a stock shoots higher, value investors justifiably hesitate on trading it. The stock priced in the good news already, leaving few extra gains ahead. So when Mylan N.V. (NASDAQ: MYL) rose by over 15% on the week, the best thing investors may do before buying Mylan stock is to look at the quarterly earnings result in detail.

  • Mylan: Why North America Is a Major Market
    Market Realist11 days ago

    Mylan: Why North America Is a Major Market

    In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.

  • Mylan’s Earnings Projections in 2018
    Market Realist12 days ago

    Mylan’s Earnings Projections in 2018

    According to Mylan’s (MYL) third-quarter earnings conference call, the company expects to witness an adjusted EPS of $4.55–$4.90 in 2018. Wall Street analysts expect Mylan to report an adjusted EPS of $4.70 in 2018, which will be a rise of 2.99% YoY. Wall Street analysts also expect Mylan to report an adjusted EPS of $5.59 in 2020, which will be a rise of 8.47% YoY.

  • Analyzing Mylan’s Revenue Projections in 2018
    Market Realist12 days ago

    Analyzing Mylan’s Revenue Projections in 2018

    According to Mylan’s (MYL) third-quarter earnings conference call, the company expects to witness revenues of $11.25 billion–$12.25 billion in 2018. Wall Street analysts expect Mylan to report revenues of $11.50 billion in 2018, which will be a decline of 3.44% YoY. Wall Street analysts also expect Mylan to report revenues of $12.46 billion in 2020, which will be a rise of 3.72% YoY.

  • Motley Fool12 days ago

    Momenta Pharmaceuticals Inc (MNTA) Q3 2018 Earnings Conference Call Transcript

    MNTA earnings call for the period ending September 30, 2018.

  • Mylan: Analysts’ Recommendations in November
    Market Realist12 days ago

    Mylan: Analysts’ Recommendations in November

    On November 6, Mylan (MYL) closed at $36.43, which was 16.13% higher than its previous closing price. The stock was trading 12.33% higher than its closing price of $32.43 on November 1. Based on Mylan’s closing price on November 6, the company witnessed returns of 16.35% in the last week, 3.17% in the last month, and -7.14% in the last quarter.

  • Company News For Nov 7, 2018
    Zacks12 days ago

    Company News For Nov 7, 2018

    Companies In The News Are: ELF,ABC,MNK,MYL

  • Wall Street thought Mylan was headed for disaster—now, analysts are raving
    MarketWatch12 days ago

    Wall Street thought Mylan was headed for disaster—now, analysts are raving

    Generic drugmaker Mylan’s last quarterly report was marked by poor financial results and other discouraging developments, leading many investors to worry that the sky was falling, according to Leerink analyst Ami Fadia. Mylan’s (MYL)third-quarter results, which included a profit beat, sent the company’s shares up 16% on Tuesday and spurred a turnaround in Wall Street sentiment. “Bigger picture, we see recent weakness in MYL as overdone,” said J.P. Morgan analyst Chris Schott.

  • 3 Big Stock Charts for Wednesday: Walt Disney, Skyworks Solutions and PG&E Corporation
    InvestorPlace12 days ago

    3 Big Stock Charts for Wednesday: Walt Disney, Skyworks Solutions and PG&E Corporation

    Election day was unsurprisingly tame, with most investors willing to wait at least one more day to make trades so they can make some decisions in light of who is (or isn’t) in office. Click to Enlarge • The weekly chart isn’t tough to interpret.

  • Barrons.com12 days ago

    The Market Is Finally Embracing Long-Unloved Drug Stocks

    Bausch Health, Mallinckrodt, and Mylan have rallied after years in the doghouse. Mylan could be the next to rebound.

  • Reuters12 days ago

    US STOCKS-S&P 500 futures up as Democrats capture U.S. House

    U.S. stock futures held onto gains on Tuesday after media projections showed the Democrats winning control of the House of Representatives in U.S. midterm congressional elections. With President Donald Trump's Republican party holding onto their majority in the Senate, according to CNN, NBC and ABC News, the results were in line with expectations on Wall Street that Washington was set for gridlock.